Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2017, Article ID 4191670, 10 pages
https://doi.org/10.1155/2017/4191670
Review Article

Efficacy and Safety of Cerebrolysin for Acute Ischemic Stroke: A Meta-Analysis of Randomized Controlled Trials

Department of Neurosurgery, Shanghai Institute of Neurosurgery, PLA Institute of Neurosurgery, Changzheng Hospital, Second Military Medical University, Shanghai, China

Correspondence should be addressed to Junyu Wang; moc.361@8002emorej and Lijun Hou; moc.621@zcuohnujil

Received 16 March 2017; Accepted 9 May 2017; Published 5 June 2017

Academic Editor: John H. Zhang

Copyright © 2017 Danfeng Zhang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. J. Murray, T. Vos, R. Lozano, M. Naghavi, A. D. Flaxman, C. Michaud et al., “Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the global burden of disease study 2010,” Lancet, vol. 380, no. 9859, pp. 2197–2223, 2012. View at Google Scholar
  2. C. J. L. Murray and A. D. Lopez, “Measuring the global burden of disease,” The New England Journal of Medicine, vol. 369, no. 5, pp. 448–457, 2013. View at Publisher · View at Google Scholar · View at Scopus
  3. W. Hacke, M. Kaste, E. Bluhmki et al., “Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke,” The New England Journal of Medicine, vol. 359, no. 13, pp. 1317–1329, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. J. M. Wardlaw, V. Murray, E. Berge, and G. J. del Zoppo, “Thrombolysis for acute ischaemic stroke,” Cochrane Database of Systematic Reviews, no. 7, Article ID CD000213, 2009. View at Google Scholar · View at Scopus
  5. J. L. Saver, E. E. Smith, G. C. Fonarow et al., “The "golden hour" and acute brain ischemia: presenting features and lytic therapy in >30,000 patients arriving within 60 minutes of stroke onset,” Stroke, vol. 41, no. 7, pp. 1431–1439, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. D. B. Zahuranec and J. J. Majersik, “Percentage of acute stroke patients eligible for endovascular treatment,” Neurology, vol. 79, supplement 1, no. 13, pp. S22–S25, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. P. A. G. Sandercock, “The international stroke trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke,” Lancet, vol. 349, no. 9065, pp. 1569–1581, 1997. View at Publisher · View at Google Scholar · View at Scopus
  8. Z.-M. Chen, “CAST: Randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke,” Lancet, vol. 349, no. 9066, pp. 1641–1649, 1997. View at Publisher · View at Google Scholar · View at Scopus
  9. J. de Keyser, G. Sulter, and P. G. Luiten, “Clinical trials with neuroprotective drugs in acute ischaemic stroke: are we doing the right thing?” Trends in Neurosciences, vol. 22, no. 12, pp. 535–540, 1999. View at Publisher · View at Google Scholar · View at Scopus
  10. E. Martínez-Vila and P. I. Sieira, “Current status and perspectives of neuroprotection in ischemic stroke treatment,” Cerebrovascular Diseases, vol. 11, supplement 1, pp. 60–70, 2001. View at Publisher · View at Google Scholar · View at Scopus
  11. S.-Y. Xu and S.-Y. Pan, “The failure of animal models of neuroprotection in acute ischemic stroke to translate to clinical efficacy,” Medical Science Monitor Basic Research, vol. 28, no. 19, pp. 37–45, 2013. View at Publisher · View at Google Scholar
  12. M. Tymianski, “Novel approaches to neuroprotection trials in acute ischemic stroke,” Stroke, vol. 44, no. 10, pp. 2942–2950, 2013. View at Publisher · View at Google Scholar
  13. K.-A. Hossmann, “The two pathophysiologies of focal brain ischemia: implications for translational stroke research,” Journal of Cerebral Blood Flow and Metabolism, vol. 32, no. 7, pp. 1310–1316, 2012. View at Publisher · View at Google Scholar · View at Scopus
  14. M. Hartbauer, B. Hutter-Paier, G. Skofitsch, and M. Windisch, “Antiapoptotic effects of the peptidergic drug Cerebrolysin on primary cultures of embryonic chick cortical neurons,” Journal of Neural Transmission, vol. 108, no. 4, pp. 459–473, 2001. View at Publisher · View at Google Scholar · View at Scopus
  15. B. Gutmann, B. Hutter-Paier, G. Skofitsch, M. Windisch, and R. Gmeinbauer, “In vitro models of brain ischemia: the peptidergic drug cerebrolysin protects cultured chick cortical neurons from cell death,” Neurotoxicity Research, vol. 4, no. 1, pp. 59–65, 2002. View at Publisher · View at Google Scholar · View at Scopus
  16. C. Riley, B. Hutter-Paier, M. Windisch, E. Doppler, H. Moessler, and R. Wronski, “A peptide preparation protects cells in organotypic brain slices against cell death after glutamate intoxication,” Journal of Neural Transmission, vol. 113, no. 1, pp. 103–110, 2006. View at Publisher · View at Google Scholar · View at Scopus
  17. L. Zhang, M. Chopp, D. H. Meier et al., “Sonic hedgehog signaling pathway mediates Cerebrolysin-improved neurological function after stroke,” Stroke, vol. 44, no. 7, pp. 1965–1972, 2013. View at Publisher · View at Google Scholar · View at Scopus
  18. C. Zhang, M. Chopp, Y. Cui et al., “Cerebrolysin enhances neurogenesis in the ischemic brain and improves functional outcome after stroke,” Journal of Neuroscience Research, vol. 88, no. 15, pp. 3275–3281, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. J. Ren, D. Sietsma, S. Qiu, H. Moessler, and S. P. Finklestein, “Cerebrolysin enhances functional recovery following focal cerebral infarction in rats,” Restorative Neurology and Neuroscience, vol. 25, no. 1, pp. 25–31, 2007. View at Google Scholar · View at Scopus
  20. D. C. Jianu, D. F. Muresanu, O. Bajenaru et al., “Cerebrolysin adjuvant treatment in Broca's aphasics following first acute ischemic stroke of the left middle cerebral artery,” Journal of Medicine And Life, vol. 3, no. 3, pp. 297–307, 2010. View at Google Scholar · View at Scopus
  21. M. R. Amiri-Nikpour, S. Nazarbaghi, B. Ahmadi-Salmasi, T. Mokari, U. Tahamtan, and Y. Rezaei, “Cerebrolysin effects on neurological outcomes and cerebral blood flow in acute ischemic stroke,” Neuropsychiatric Disease and Treatment, vol. 10, pp. 2299–2306, 2014. View at Publisher · View at Google Scholar · View at Scopus
  22. D. F. Muresanu, W.-D. Heiss, V. Hoemberg et al., “Cerebrolysin and recovery after stroke (CARS): a randomized, placebo-controlled, double-blind, multicenter trial,” Stroke, vol. 47, no. 1, pp. 151–159, 2016. View at Publisher · View at Google Scholar · View at Scopus
  23. L.-X. Xue, T. Zhang, Y.-W. Zhao, Z. Geng, J.-J. Chen, and H. Chen, “Efficacy and safety comparison of DL-3-n-butylphthalide and cerebrolysin: effects on neurological and behavioral outcomes in acute ischemic stroke,” Experimental and Therapeutic Medicine, vol. 11, no. 5, pp. 2015–2020, 2016. View at Publisher · View at Google Scholar · View at Scopus
  24. W.-D. Heiss, M. Brainin, N. M. Bornstein, J. Tuomilehto, and Z. Hong, “Cerebrolysin in patients with acute ischemic stroke in asia: results of a double-blind, placebo-controlled randomized trial,” Stroke, vol. 43, no. 3, pp. 630–636, 2012. View at Publisher · View at Google Scholar · View at Scopus
  25. D. Moher, A. Liberati, J. Tetzlaff, and D. G. Altman, “Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement,” British Medical Journal, vol. 339, article b2535, 2009. View at Publisher · View at Google Scholar · View at Scopus
  26. J. P. Higgins and S. Green, “Cochrane handbook for systematic reviews of interventions,” version 5.1.0, The Cochrane Collaboration, http://www.cochrane-handbook.org, 2011. View at Publisher · View at Google Scholar
  27. J. P. T. Higgins, S. G. Thompson, J. J. Deeks, and D. G. Altman, “Measuring inconsistency in meta-analyses,” British Medical Journal, vol. 327, no. 7414, pp. 557–560, 2003. View at Publisher · View at Google Scholar · View at Scopus
  28. M. Egger, G. D. Smith, M. Schneider, and C. Minder, “Bias in meta-analysis detected by a simple, graphical test,” British Medical Journal, vol. 315, no. 7109, pp. 629–634, 1997. View at Publisher · View at Google Scholar · View at Scopus
  29. G. Ladurner, P. Kalvach, and H. Moessler, “Neuroprotective treatment with Cerebrolysin in patients with acute stroke: a randomised controlled trial,” Journal of Neural Transmission, vol. 112, no. 3, pp. 415–428, 2005. View at Publisher · View at Google Scholar · View at Scopus
  30. W. Lang, C. H. Stadler, Z. Poljakovic et al., “A prospective, randomized, placebo-controlled, double-blind trial about safety and efficacy of combined treatment with alteplase (rt-PA) and Cerebrolysin in acute ischaemic hemispheric stroke,” International Journal of Stroke, vol. 8, no. 2, pp. 95–104, 2013. View at Publisher · View at Google Scholar · View at Scopus
  31. E. Schauer, R. Wronski, J. Patockova et al., “Neuroprotection of Cerebrolysin in tissue culture models of brain ischemia: post lesion application indicates a wide therapeutic window,” Journal of Neural Transmission, vol. 113, no. 7, pp. 855–868, 2006. View at Publisher · View at Google Scholar · View at Scopus
  32. D. F. Muresanu, A. Buzoianu, S. I. Florian, and T. von Wild, “Towards a roadmap in brain protection and recovery,” Journal of Cellular and Molecular Medicine, vol. 16, no. 12, pp. 2861–2871, 2012. View at Publisher · View at Google Scholar · View at Scopus
  33. L. E. U. Ziganshina and T. Abakumova, “Cerebrolysin for acute ischaemic stroke,” The Cochrane Database of Systematic Reviews, vol. 6, Article ID Cd007026, 2015. View at Publisher · View at Google Scholar · View at Scopus